The Antibiotics for Children With Severe Diarrhoea (ABCD) trial project led by WHO is a multi-site randomized, double-bind, placebo-controlled clinical trial attempting to evaluate the ability of an antibiotic (azithromycin) in reducing mortality within 90 days of the acute diarrhoeal episode and improve nutritional status over the same period.Read More >
What We Do
The International Vaccine Access Center accelerates equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.
Our Approach Blends
- Rigorous science
- Productive partnership
- Clear communication
- Capacity building and training
Our Practice Areas
Based on demand from country leaders and health agencies around the world, we provide independent policy advice, support country vaccine decision-making and governance, and connect partners to accelerate progress toward health and development goals.
Coverage & Equity
To improve equitable immunization within and between countries, we help countries better measure vaccine coverage, interpret results for action, and boost demand for vaccination using novel strategies.
Major studies evaluate the feasibility of using blood samples to identify gaps in immunity and implement mobile-based reminder systems, two approaches that could be adopted by governments to strengthen vaccination programs and protect all children.
To inform and improve prevention and control strategies, we manage large clinical studies and surveillance networks. We also quantify the amount of disease in countries and globally via mathematical models constructed with an understanding of population-level epidemiology, health system, and policy contexts.
Economics & Finance
To support investment and funding decisions, we quantify the cost of illness from diseases and determine the economic return on investment of vaccine use. We also help countries identify and address financing and affordability challenges.
To inform policy & investments, we evaluate how vaccines reduce the spread of disease and create other value post introduction and over time.
To support the introduction of new vaccines and improvements in coverage, we analyze the programmatic and logistical implications of policy choices, such as variations in shipping, packaging, and other operational decisions that affect cost and health impact. Digital tools aid countries in designing, planning, and improving supply chains.
As a leading contributor to global immunization policy, we synthesize & present evidence to build consensus, inform strategy and support policy development. Members of IVAC’s leadership serve on the WHO Strategic Advisory Group of Experts (SAGE) and on several WHO working groups.
To advance evidence-based policy, we support technically driven efforts, led by global and in-country partners, to understand the value of vaccines. We develop compendiums of published evidence, formulate messaging, and develop advocacy materials. We also build and manage coalitions and networks of scientists and other health advocates.
Evaluation of Baltimore City Health Department Influenza Immunization Initiative Challenge There is concern about an increase in rates of both influenza and COVID-19 illnesses and deaths this coming 2020-2021 flu season and Baltimore City has committed to reaching the ambitious target of vaccinating at least 70% of its residents against influenza. Last season, although reporting […]Read More >
Policy makers may be better able to evaluate the progress of measles elimination and rubella control programs by understanding population immunity through large-scale serological surveys. This is a collaborative study led by the Indian Council of Medical Research.Read More >
The study will elucidate the novel problem of missed opportunities during hospitalization by quantifying the proportion of under-vaccinated children who remain unvaccinated at the time of hospital discharge. Our study is designed to systematically collect the vaccination status of hospitalized children at the time of admission and discharge, while also documenting caregivers’ and healthcare providers’ perspectives on barriers to vaccine access.Read More >
This study will establish and maintain a surveillance network to measure the impact of routine infant vaccination with PCV on serotypes causing invasive pneumococcal disease among young children under 5 years of age in India.Read More >